Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators-Reference-Cited by-同舟云学术

Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators

Published:2012-02-27 Issue:9 Volume:55 Page:4027-4061
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pirat Céline¹,Farce Amaury¹,Lebègue Nicolas¹,Renault Nicolas¹,Furman Christophe²,Millet Régis²,Yous Saı̈d¹,Speca Silvia³,Berthelot Pascal¹,Desreumaux Pierre³,Chavatte Philippe¹²

Affiliation:

1. Laboratoire de Chimie Thérapeutique, Faculté des Sciences Pharmaceutiques et Biologiques, Université Lille-Nord de France, EA 4481, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France

2. Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille-Nord de France, EA 4481, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France

3. Faculté de Médecine, Amphis J et K, Université Lille-Nord de France, INSERM U995, Boulevard du Professeur Jules Leclerc, 59045 Lille Cedex, France

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm101360s

Reference181 articles.

1. The metabolic syndrome

2. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions

3. PPARs: therapeutic targets for metabolic disease

4. The next generation of PPAR drugs: Do we have the tools to find them?

5. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism

Cited by 166 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Loss of PPARγ Expression and Signaling Is a Key Feature of Cutaneous Actinic Disease and Squamous Cell Carcinoma: Association with Tumor Stromal Inflammation;Cells;2024-08-15

2. PPARγ regulates PNPLA3 in adipocytes in vitro and in vivo in healthy obese patients and mice with metabolic dysfunction-associated steatohepatitis;2024-08-09

3. Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation;Life Sciences;2024-08

4. Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis;European Journal of Medicinal Chemistry;2024-04

5. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells;Biochemical Pharmacology;2024-04